Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moFOSFOMYCIN TROMETHAMINE (fosfomycin tromethamine) by Aurobindo Pharma is clinical pharmacology absorption fosfomycin tromethamine is rapidly absorbed following oral administration and converted to the free acid, fosfomycin. Approved for pyelonephritis, perinephric abscess. First approved in 2024.
CLINICAL PHARMACOLOGY Absorption Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to the free acid, fosfomycin. Absolute oral bioavailability under fasting conditions is 37%. After a single 3-gram dose of fosfomycin tromethamine, the mean (± 1 SD) maximum…
Worked on FOSFOMYCIN TROMETHAMINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo